Ionophoric effects of the antitubercular drug bedaquiline
Author(s) -
Kiel Hards,
Duncan G. G. McMillan,
Lici A. Schurig-Briccio,
Robert B. Gennis,
Holger Lill,
Dirk Bald,
Gregory M. Cook
Publication year - 2018
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1803723115
Subject(s) - bedaquiline , atp synthase , escherichia coli , biochemistry , drug discovery , chemistry , liposome , transmembrane protein , adenosine triphosphate , biophysics , biology , enzyme , receptor , tuberculosis , mycobacterium tuberculosis , medicine , gene , pathology
Bedaquiline (BDQ), an inhibitor of the mycobacterial F 1 F o -ATP synthase, has revolutionized the antitubercular drug discovery program by defining energy metabolism as a potent new target space. Several studies have recently suggested that BDQ ultimately causes mycobacterial cell death through a phenomenon known as uncoupling. The biochemical basis underlying this, in BDQ, is unresolved and may represent a new pathway to the development of effective therapeutics. In this communication, we demonstrate that BDQ can inhibit ATP synthesis in Escherichia coli by functioning as a H + /K + ionophore, causing transmembrane pH and potassium gradients to be equilibrated. Despite the apparent lack of a BDQ-binding site, incorporating the E. coli F o subunit into liposomes enhanced the ionophoric activity of BDQ. We discuss the possibility that localization of BDQ at F 1 F o -ATP synthases enables BDQ to create an uncoupled microenvironment, by antiporting H + /K + Ionophoric properties may be desirable in high-affinity antimicrobials targeting integral membrane proteins.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom